Introduction
Epilepsy is a chronic neurological disorder characterized by predisposition to recurrent seizures. 1 Epidemiological studies have
shown that patients with epilepsy have an increased mortality compared with the general population, with cardiovascular disease (CVD) being a significant cause of death. [2] [3] [4] Furthermore, epilepsy has been associated with a higher risk of CVD-related events. [4] [5] [6] Of note, seizures may occur following cerebrovascular events and especially after major strokes and sinus thrombosis. 7 In addition, patients with autoimmune diseases such as systemic lupus erythematosus, Sjogren's syndrome, Crohn's and Behcet's disease, which have been also linked to increased CVD risk, 8, 9 can present with epilepsy. 10 Seizures may also be the first clinical manifestation of brain arteriovenous malformations, especially when they are located in the frontal and temporal lobes. 11 Whether established vascular risk factors (e.g. hypertension and activated hemostasis) and more speculative ones (e.g. lipid oxidation) 11 play a significant role in bleeding or thrombus formation related to such malformations is not clearly established.
The association between epilepsy and CVD morbidity and mortality is not clearly defined. In this context, antiepileptic drugs (AEDs) may differentially influence CVD risk in patients with epilepsy. Furthermore, a link between epilepsy, AEDs and cardiac arrhythmias has also been proposed that may be responsible for sudden unexpected death in epilepsy (SUDEP) in such patients.
Another possible explanation for the link between epilepsy and CVD is that patients with epilepsy are more likely to be cigarette smokers compared with individuals without epilepsy. 12, 13 Smoking is a predictor of arterial stiffness 14 that affects all arteries.
Furthermore, patients with epilepsy tend to exercise less and adopt unhealthy dietary habits. 12, 13 This behaviour predisposes them to increased CVD risk as both physical activity and a balanced diet, such as the Mediterranean diet, have been associated with improvements in several CVD risk factors. 16, 17 Recently leucocyte adhesion in the brain parenchyma has been related to seizure induction. 18 In this context, the development of interventions targeting this brain leucocyte trafficking may represent a novel therapeutic strategy for epilepsy. 19 Seizures cause endothelial sloughing from cerebral vessels resulting in brain-derived circulating endothelial cells (BCECs) in the fraction of peripheral blood mononuclear cells. 20 BCECs are possible early indicators of cerebral vascular damage after epileptic seizures. 20 This narrative review considers the influence of AEDs on arrhythmias and SUDEP as well as on some predictors of vascular risk [i.e. weight, insulin resistance, metabolic syndrome (MetS), lipids, lipoprotein (a) (LP(a)), C-reactive protein (CRP), homocysteine (Hcy), vitamins, coagulation factors, uric acid, carotid intima media thickness (cIMT), markers of oxidative status and matrix metalloproteinase-9 (MMP-9)].
Search methods
We searched MEDLINE up to December 1, 2013 for relevant publications using combinations of the following keywords: epilepsy, antiepileptic drugs, arrhythmias, sudden unexpected death, weight, insulin resistance, metabolic syndrome, lipids, lipoprotein (a), C-reactive protein, homocysteine, folate, vitamin B6, vitamin B12, vitamin D, plasminogen activator inhibitor-1, tissue plasminogen activator antigen, von Willebrand factor, fibrinogen, coagulation factors, uric acid, carotid intima media thickness, markers of oxidative status and matrix metalloproteinase-9.
We also examined the reference list of articles identified by this search and selected those we judged relevant. These were included in this narrative review. Overall, we concentrated on recent publications (the vast majority are dated after 1990).
Epilepsy, AEDs and SUDEP
Patients with epilepsy may be susceptible to cardiac arrhythmias due to both genetic predisposition and/or seizure-induced chronic autonomic dysfunction. 21, 22 Furthermore, such arrhythmias could be aggravated by the presence of coronary heart disease (CHD) and ischaemia due to atherosclerosis. Certain AEDs such as phenytoin and carbamazepine have also been shown to exert proarrhythmic effects. 22 In addition, epileptic seizures have been reported to induce cardiac ischaemia both via chronic and acute effects on the heart [e.g. impaired heart rate variability, cardiac fibrosis, ST-segment depression and increased heart rate]. 22, 23 These effects have been particularly studied in cases of SUDEP which accounts for 5-30% of deaths in patients with epilepsy.
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SUDEP has been associated with fibrotic changes in the deep and subendocardial myocardium, possibly attributed to seizureinduced myocardial ischaemia, which in conjunction with seizure-derived arrhythmias may result in cardiac death. 23 Alterations in electrolytes and blood pH together with the release of catecholamines might facilitate arrhythmias.
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There is also evidence that cardiac troponin-I (cTNI) release of unknown origin occurs in patients without cardiac symptoms but with generalized seizures. 26 This cTNI rise was more prominent in patients with vascular risk factors (e.g. hypertension, hypercholesterolaemia or diabetes). 26 Although the exact pathogenesis of SUDEP remains unknown, significant risk factors include onset of epilepsy at an early age, seizure recurrence, polytherapy with AEDs and frequent dose changes. [27] [28] [29] [30] 
Effects of AEDs on weight, insulin resistance and MetS
AEDs are a diverse group of anticonvulsant agents. 41 Among them, valproic acid (valproate), carbamazepine, pregabalin, gabapentin and vigabatrin have been associated with weight increase. [42] [43] [44] [45] Possible mechanisms involved in AEDs-induced weight gain include leptin and insulin resistance, hyperinsulinaemia and increased food intake (e.g. carbohydrate craving). [46] [47] [48] [49] [50] [51] In this context, obese patients with epilepsy on valproic acid were at a higher risk of developing MetS compared with otherwise healthy obese individuals. 52 Furthermore, non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of MetS, was diagnosed by ultrasound measurement in patients on valproic acid, carbamazepine and lamotrigine monotherapy (in 60.9, 22.7 and 8.7% of treated patients, respectively). 53 However, there were no differences in insulin resistance between the study groups and TC, LDL-C, HDL-C and gamma-glutamyltransferase were significantly higher in the carbamazepine group. 53 Of note, valproic acid monotherapy has been related to NAFLD development even in adolescents. 54 These associations are of clinical importance as MetS and NAFLD are linked to increased CVD risk. [55] [56] [57] Lamotrigine, levetiracetam and phenytoin are considered weight neutral, whereas felbamate, topiramate and zonisamide were reported to decrease weight. 41, 41, 58 However, there are also conflicting results regarding the effects of certain AEDs on weight. For example, phenytoin treatment, although regarded as weight neutral, has also been associated with weight gain 45 and insulin resistance. 59 Furthermore, no significant differences in body mass index (BMI) between men with epilepsy on valproic acid, carbamazepine or oxcarbazepine monotherapy and individuals without epilepsy were reported. 60 In another study, patients with epilepsy on levetiracetam, carbamazepine or lamotrigine monotherapy for at least 6 months had significantly greater BMI compared with controls in both genders. 61 However, when analyzed separately according to the antiepileptic treatment, the differences were significant only for women on carbamazepine or on lamotrigine compared with controls. 61 As weight gain and obesity are associated with CVD risk, 62,63 the weight-related effects of AEDs may need to be considered when selecting individual antiepileptic therapy. This is especially true for patients who are already overweight/obese or at high CVD risk [e.g. those with MetS or type 2 diabetes mellitus (T2DM)]. Overall, AEDs may differentially influence weight in patients with epilepsy, subsequently affecting the development of insulin resistance, MetS and NAFLD. Table 2 summarizes these effects.
Effects of AEDs on lipid and lipoprotein (a) [Lp (a)] levels
In relation to their effects on lipid metabolism, AEDs are either enzyme-inducers, which enhance hepatic P450 cytochrome system activity, leading to increased cholesterol synthesis, or, enzyme-inhibitors, which exert the opposite action. 64 Phenytoin, phenobarbital, carbamazepine and primidone are enzyme-inducing AEDs, whereas valproate, lamotrigine and levetiracetam are enzyme-inhibitors. 64 Accordingly, in patients receiving phenytoin, total cholesterol (TC), triglycerides (TG) and low density lipoprotein cholesterol (LDL-C) levels were significantly increased compared with both controls and those on valproate. 59 Furthermore, carbamazepine monotherapy has been associated with increases in TC, LDL-C, high density lipoprotein cholesterol (HDL-C) and TG concentrations, 61,65-67 although conflicting results have been reported. 60 Interestingly, a gender effect was observed, with more pronounced increases in both HDL-C and LDL-C levels in women with epilepsy. 67 Valproate-treated patients were reported to have lower TC, LDL-C and HDL-C levels compared with subjects without epilepsy 50, 66 ; TG concentrations were either lower 66 or higher than controls. 50 In patients with epilepsy both levetiracetam and lamotrigine monotherapy did not alter TC, LDL-C and HDL-C levels, 61 although levetiracetam was shown to significantly increase LDL-C concentrations in a recent study. 68 Women on valproate had lower HDL-C concentrations compared with those on carbamazepine, lamotrigine or topiramate, 69 higher TG and lower TC and LDL-C levels compared with those on carbamazepine 70 and lower TC, LDL-C and HDL-C concentrations compared with those on lamotrigine. 71 Replacement of carbamazepine with oxcarbazepine, apart from normalization of the hepatic P450 cytochrome system activity (as assessed by changes in half-life levels and clearance of antipyrine), resulted in a significant decrease in TC levels, although HDL-C and TG concentrations remained unchanged. 72 In contrast, oxcarbazepine monotherapy was recently reported to significantly increase LDL-C levels in another study. 68 Furthermore, switching from either phenytoin or carbamazepine to either lamotrigine or levetiracetam monotherapy produced significant decreases in TC, TG and non-HDL-C levels in patients with epilepsy [p < 0.0001 for all comparisons]. 73 A modest but significant decrease in HDL-C concentrations was also observed in patients who switched from carbamazepine to either lamotrigine or levetiracetam monotherapy [mean reduction = 6 mg/dl; p = 0.001]. 73 Carbamazepine monotherapy has been associated with increased Lp (a) levels. 65 Interestingly, in patients with epilepsy who stopped carbamazepine, Lp (a) concentrations decreased significantly [À30.6%; p = 0.0004]. 73 The effects of phenobarbital, carbamazepine and valproate on Lp (a) levels have been studied mainly in children with reports of increased concentrations in some but not all studies. [74] [75] [76] As lipid abnormalities are associated with increased CVD risk, applying lifestyle measures and the use of lipid lowering drugs may be beneficial in patients with epilepsy, especially if long-term compliance is maintained. 77 The clinical relevance of decreasing high circulating levels of Lp (a) is debated. 78 However, it has been suggested that the co-administration of statins with enzymeinducing AEDs may reduce statin effectiveness in achieving LDL-C targets. 79, 80 The efficacy of other drugs used in patients at risk of vascular disease (e.g. antihypertensives and anticoagulants) may be affected by AEDs. 79 Studies have shown that phenytoin reduced the efficacy of several statins (e.g. atorvastatin, fluvastatin and simvastatin) leading to the administration of the highest doses without successful control of TC. 81, 82 Therefore, the use of enzymeinducing AEDs may require higher doses of statins compared with AEDs that inhibit or do not influence hepatic enzymes involved in statin metabolism. However, data are scarce in this field. 64 The combination of ezetimibe with a statin may provide the additional lipid-lowering effect needed to reach LDL-C goals without using the highest dose of statins. 83 No studies that assessed the pharmacokinetics of ezetimibe and AEDs were found. Pharmacokinetic interactions may affect the metabolism of drugs that influence vascular risk (e.g. losartan). 84, 85 A more detailed discussion of these issues is beyond the scope of this review. Overall, certain AEDs may increase lipids and Lp (a) levels, whereas others may not. Table 3 summarizes these effects. 
Effects of AEDs on C-reactive protein (CRP), homocysteine (Hcy), vitamins and coagulation factors
CRP is considered a marker of atherosclerosis 86, 87 and a predictor of vascular risk. [88] [89] [90] Therefore, the effects of AEDs on CRP levels are important. Patients with epilepsy on several AEDs (mostly valproate, carbamazepine, lamotrigine and phenytoin) were reported to have higher serum CRP concentrations compared with individuals without epilepsy. 91 Furthermore, in people with epilepsy, switching from either phenytoin or carbamazepine to either lamotrigine or levetiracetam monotherapy was associated with a significant 31.4% reduction in CRP levels (p = 0.027). 73 Of note, this change in CRP concentrations correlated with significant reductions in Lp (a) (r = 0.43; p = 0.002) and HDL-C levels (r = 0.327; p = 0.023) observed in those patients who stopped carbamazepine. 73 High levels of Hcy (i.e. hyperhomocysteinemia) are associated with hypercoagulability 92 and vascular disease risk. 93 Furthermore, increased Hcy concentrations were shown to enhance seizure activity. 94 In this context, it has been suggested that Hcy is pro-convulsant and may influence the response to AEDs. 94 Interestingly, patients on phenytoin monotherapy had significantly higher Hcy levels compared with patients on other AEDs (i.e. carbamazepine, valproate and lamotrigine) or with patients on polytherapy. 101 Furthermore, in individuals with epilepsy who stopped phenytoin, Hcy concentrations decreased significantly (p = 0.005), whereas in those taken off carbamazepine no significant changes were found. 73 Only patients on phenytoin had higher, although not significant, baseline Hcy levels compared with controls. These observations highlight the need to establish the importance of screening Hcy concentrations both before and during antiepileptic therapy. Furthermore, genetic polymorphisms of the methylenetetrahydrofolate reductase (MTHFR) enzyme activity may affect Hcy concentrations in patients with epilepsy; the CT677/AC1298 and TT677/AA1298 diplotypes have been associated with the presence of hyperhomocysteinemia in epileptic patients on enzyme-inducing AEDs, whereas the CC677/AA1298 diplotype was more frequent in controls. 102 Such polymorphisms may also influence the response to folate supplementation; epileptic patients on enzyme-inducing AEDs with the MTHFR677TT/ 1298AA polymorphism, although having normal plasma folate and Hcy levels following 1 month of folate supplementation (5 mg/ day), exhibited hyperhomocysteinemia at 6 months. 103 The mechanism by which AEDs increase Hcy concentrations may involve the depletion of folate, vitamins B6 and B12 [i.e. cofactors in the metabolism of homocysteine]. 99, 101 98 In contrast, valproate was shown to increase vitamin B12 levels. 106, 107 Of note, in patients with epilepsy on phenytoin, valproate or carbamazepine monotherapy, serum folate and vitamin B12 levels did not differ between those with and those without CVD. 108 Whether AEDs-induced changes in these vitamin levels are translated to a higher risk of CVD events remains to be established. Furthermore, the clinical relevance of multivitamin supplementation in CVD risk reduction remains controversial. 109 Nevertheless, some, but not all, investigators support the use of multivitamin supplementations in patients with epilepsy on AEDs, 110-112 along with a ketogenic diet which is known to exert antiseizure effects. 113 Furthermore, in order to prevent spontaneous abortion and congenital malformations, women with epilepsy who might become pregnant are recommended to receive at least 0.4 mg/day folate supplementation, 114 especially those taking valproate. 115 Attention should be paid in patients on phenytoin, as folate supplementation increases the metabolism of phenytoin, thus decreasing its serum concentration to subtherapeutic levels. 116 Elevated Hcy levels have been related to increased plasminogen activator inhibitor-1, tissue plasminogen activator antigen, von Willebrand (vW) factor and fibrinogen levels. 117 Patients with epilepsy on carbamazepine or valproate monotherapy were reported to have significantly higher fibrinogen concentrations compared with controls. 118 Patients treated with carbamazepine had also higher vW factor activity levels compared with the control group. 118 In general, valproate treatment has been associated with coagulopathies [e.g. acquired vW disease and thrombocytopenia]. 119, 120 Therefore, impaired fibrinolysis and enhanced coagulopathy may represent another possible mechanism of AED-induced hyperhomocysteinemia. However, in one study phenytoin therapy was shown to reduce fibrinogen levels, 121 despite increasing Hcy levels in other reports.
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Interestingly, enzyme-inducing AEDs (e.g. carbamazepine and phenytoin) have been associated with increased bone turnover 122, 123 and fracture rates. 123 These effects may partly be attributed to AEDs-induced reduction in 25-hydroxyvitamin D levels. 124 Furthermore, vitamin D has been reported to exert anticonvulsant properties, a finding that supports the prophylactic use of vitamin D in patients with epilepsy on AEDs. 125 The possible link between vitamin D deficiency and atherosclerosis 126, 127 should also be considered in patients with epilepsy. Overall, AEDs can influence CRP, Hcy, vitamins and coagulation factors in patients with epilepsy. Table 4 summarizes these effects.
Effects of AEDs on uric acid, cIMT and markers of oxidative status
Elevated levels of serum uric acid (SUA) have been associated with CVD risk, 56, [128] [129] [130] a finding at least partly attributed to its pro-inflammatory and pro-oxidant properties. 129, 130 In this context, valproate monotherapy has been associated with 141 It is therefore of interest that carbamazepine, phenytoin and valproic acid but not lamotrigine monotherapy, significantly increased cIMT. 142 Furthermore, cIMT was significantly thicker in men than in women with epilepsy. 91 In the same study, apart from age, gender and oxidative stress, duration of AED therapy was independently associated with cIMT, 91 thus suggesting that long-term exposure to AEDs may be implicated in the development of atherosclerosis. However, conflicting data also exist. 143 Of note, in some studies significant increases in cIMT have been observed in children with epilepsy on valproic acid compared with healthy children, despite no differences in lipid profiles. 144 Oxidative stress contributes to the progression of atherosclerosis 145, 146 and the development of CVD. 147 Several biomarkers of oxidative status are reported to predict CVD risk. 148, 149 However, the role of antioxidant multivitamins supplementation on CVD risk reduction remains controversial. 109 In this context, valproate, carbamazepine and phenobarbital treatment has been associated with elevated levels of oxidative stress biomarkers (i.e. oxidized-LDL, malondialdehyde, thiobarbituric reactive substances, lipid hydroperoxide and asymmetric dimethylarginine) and decreased total antioxidant capacity. 91, 106, 118, 131, 150, 151 However, available data regarding the effects of AEDs on oxidative stress markers are scarce and therefore no conclusions can be made. Overall, AEDs may differentially affect SUA, cIMT and oxidative stress markers in patients with epilepsy. Table 5 summarizes these effects.
8. Matrix metalloproteinase-9 (MMP-9) and epilepsy MMP-9 may contribute to arterial aneurysm formation and atherosclerosis [e.g. plaque development and destabilization]. 152 In epilepsy animal models MMP-9 induction is associated with homeostatic synaptic plasticity. 153 Furthermore, MMP-9 was upregulated in the hippocampal dentate gyrus after kainatemediated seizures. 154 Therefore, it has been hypothesized that MMP-9 may be a therapeutic target for epilepsy. 155 In this context, statins (e.g. atorvastatin and lovastatin) have been recognized as drugs that may exert anti-seizure effects. 156 In turn, these drugs (e.g. simvastatin) decrease MMP-9 activity. 157 We did not find any literature regarding AEDs and MMP-9 activity. The above mentioned findings link the aetiology of atherosclerosis with that of epilepsy, as well as the treatment of vascular disease (i.e. with statins) with a potential anti-epileptogenic effect. Of note, statin use was shown to decrease the risk of hospitalization for epilepsy. 158 However, the effects of statins on epilepsy remain a subject of debate. 159 
Conclusions
Evidence of a link between epilepsy and increased CVD morbidity and mortality, has been available for several decades. 160 Despite that, there is still a substantial need for definitive recommendations to optimize prevention for these patients. Earlier studies are limited; for example, several AEDs included in the present review were not available then. Furthermore, emerging vascular risk factors were often not considered and established vascular risk factors were less commonly assessed. Also, some drugs currently used for prevention of vascular disease were not available and treatment targets were markedly different. Even diagnostic tools for vascular disease were less advanced.
It is difficult to assess vascular risk in patients with epilepsy because the excess risk has not been definitively quantified or recognized by the guidelines of learned societies. We suggest the usual risk assessment with consideration that an additional risk may exist in patients with epilepsy. The choice of AEDs may also need to be considered in patients with metabolic or other vascular risk factors. In this context, the present review discusses the properties of AEDs that may not be favourable for patients already at a higher risk of vascular events.
AEDs may exert different effects on various established and emerging predictors of vascular risk [i.e. weight, lipids, Lp (a), CRP, Hcy, vitamins, coagulation factors, uric acid, markers of oxidative status and MMP-9]. Furthermore, pharmacokinetic interactions between AEDs and drugs used to reduce vascular risk (e.g. statins) need to be better documented. Whether this knowledge, in terms of individualizing antiepileptic and CVD prevention treatment, will prove to be relevant in clinical practice remains to be established.
Patients with epilepsy may represent another population with high vascular risk; a fact possibly not yet fully perceived by health care providers.
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